Compare Mesoblast Limited (MESO) vs Hyperliquid Strategies Inc Common Stock (PURR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Hyperliquid Strategies Inc Common Stock — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while Hyperliquid Strategies Inc Common Stock trades at $11.11 (market cap $2.24B). The key difference: Hyperliquid Strategies Inc Common Stock is the larger of the two by market cap, and Hyperliquid Strategies Inc Common Stock is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Hyperliquid Strategies Inc Common Stock for 1 Days on average.
| MESO | PURR | |
|---|---|---|
Market Cap | $1.75B | $2.24B |
Volume | 239,027 | 14,135,020 |
Sector | Health | Financials |
52-Week High | $20.96 | $14.09 |
52-Week Low | $13.19 | $3.10 |
Typical Hold Time | 15 Days | 1 Days |
Enterprise Value | $1.83B | $2.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Hyperliquid Strategies Inc Common Stock
Hyperliquid Strategies is a digital asset treasury company focused on managing a treasury of HYPE tokens, the native digital assets of the Hyperliquid Layer-1 blockchain.
Read more on PURR →
